EDN1 and systemic sclerosis: Some in vitro evidence suggests that ET-1 might promote EndoMT on ECs isolated from SSc patients and macitentan, a dual endothelin-1 receptor antagonist, blocks the EndoMT induced in vitro by the combination of TGF-β and ET-1 [116].